RxDoctor Payments Data

Craig Karpman, MD

Pulmonary Disease · Saint Louis, MONPI 1780849190

Payments from drug & device makers

$338in general payments, 2019–2025

Across 18 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$72
  • ANI Pharmaceuticals, Inc.$59
  • GSK$59
  • Bayer$41
  • Pfizer$33
  • Medtronic$24
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$32696%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$338 in reported general payments places this provider in the 25th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$123,253
Medicare patients
581
Services billed
1,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag48$1,105,444
Trelegy ElliptaFluticasone/Umeclidin/Vilanter567$502,112
OfevNintedanib Esylate30$391,580
OpsumitMacitentan23$297,167
Dupixent PenDupilumab57$274,798
Pirfenidone35$141,334
Breztri AerosphereBudesonide/Glycopyr/Formoterol147$123,900
Breo ElliptaFluticasone/Vilanterol230$120,666
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr152$101,053
Spiriva RespimatTiotropium Bromide98$83,431
EliquisApixaban76$60,126
Ambrisentan30$56,232
NucalaMepolizumab15$55,460
Spiriva HandihalerTiotropium Bromide59$54,620
SymbicortBudesonide/Formoterol Fumarate145$48,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta$59$826,6751,084 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$72$178,194305 claims
PfizerEliquis$33$60,12676 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →